10-Hydroxy-2-decenoic acid from Royal jelly: A potential medicine for RA

Aim of the studyRheumatoid arthritis synovial fibroblasts (RASFs) are known to produce matrix metalloproteinases (MMPs) and cause joint destruction. The purpose of this study is to develop a potential medicine for rheumatoid arthritis (RA).Materials and methodsTo this end, first, the MMPs inhibition factor was purified from an alkali-solubilized fraction of RJ (Apis mellifera) by C18 reverse-phase column chromatography and identified as 10-hydroxy-2-decenoic acid (10H2DA) by LTQ XL analysis. Next, Experimental test 10H2DA how to inhibited the activities of MMPs: with RASFs isolated from rheumatoid tissues by enzymatic digestion, cultures in monolayers were treated with 10H2DA (0.5 mM, 1 mM, and 2 mM) or PBS for 2 h followed by stimulation with TNF-α (10 ng/ml) for 2 h, mRNA. Protein levels of MMP-1 and MMP-3 were measured by real-time PCR and enzyme-linked immunosorbent assay (ELISA), the DNA-binding activity of activator protein-1 (AP-1) and nuclear factor κB (NF-κB) by electrophoretic mobility shift assay (EMSA), and the protein kinase activity of p38, ERK and JNK by kinase assay.ResultsThe molecular investigation revealed that the 10H2DA-mediated suppression was likely to occur through blocking p38 kinase and c-Jun N-terminal kinase–AP-1 signaling pathways. In contrast, 10H2DA had no effect on extracellular signal-regulated kinase activity, NF-κB DNA-binding activity and IκBα degradation.ConclusionThese results suggest that 10H2DA may be of potential therapeutic value in inhibiting joint destruction in RA.

Chemical structures of 10-hydroxy-trans-2-decenoic acid (10H2DA).Figure optionsDownload as PowerPoint slide